Trial Profile
Randomized, open-labelled study evaluating the antiviral efficacy, safety, and tolerability of continuing lamivudine therapy or switching to entecavir in subjects with chronic hepatitis B with detectable HBV [hepatitis B virus] DNA.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 17 Oct 2016
Price :
$35
*
At a glance
- Drugs Entecavir (Primary) ; Lamivudine (Primary)
- Indications Hepatitis B
- Focus Therapeutic Use
- 07 May 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 04 Jan 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 19 Mar 2008 New trial record.